Page last updated: 2024-11-05

thalidomide and Infarct

thalidomide has been researched along with Infarct in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects."5.39Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013)
"Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects."1.39Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dangouloff-Ros, V1
Cervera, P1
Carbonell, N1
Arrivé, L1

Other Studies

1 other study available for thalidomide and Infarct

ArticleYear
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

    Topics: Angiogenesis Inhibitors; Focal Nodular Hyperplasia; Humans; Infarction; Lenalidomide; Liver; Liver C

2013